TGFB1 and glomerulosclerosis: Pioglitazone treatment reduced the TGF-β1 induced glomerulosclerosis and tubulointerstitial damage by 30% and by 50%, respectively (Fig. 1d and e), and normalized fibronectin expression (Fig. 1f).